Tesamorelin — (2mg)
$60.00
Tesamorelin (2mg) is a synthetic 44-amino acid analog of growth hormone-releasing hormone (GHRH), modified with a trans-3-hexenoic acid group at the N-terminus that protects it from enzymatic degradation and extends its metabolic stability. It is the only FDA-approved GHRH analog —approved under the brand name Egrifta for HIV-associated lipodystrophy — and carries the most extensive human clinical evidence base of any GHRH peptide currently available for laboratory research. Manufactured in a cGMP-certified US facility. Independently third-party tested. For laboratory research use only.
In stock
10 reviews for Tesamorelin — (2mg)
Only logged in customers who have purchased this product may leave a review.
Anna Patel –
The lyophilized powder was intact and properly sealed upon arrival, with no signs of moisture or damage. Reconstitution was straightforward under controlled lab conditions, and the solution appeared clear with no visible particulates.
James Rodríguez –
Packaging was secure and discreet, with adequate insulation to protect the contents during transit. Overall, a smooth procurement experience and the material met expected research standards for handling and preparation.
Sophie Nguyen –
he vial arrived well-sealed and properly packaged with protective insulation, which I appreciated. Labeling was clear and the lyophilized powder appeared consistent and intact upon inspection.
Michael Thompson –
Overall, the product met expectations for research application and I would consider ordering again for future studies.
Laura Garcia –
Stability held consistent under proper storage conditions throughout the testing period. Packaging was secure and well-sealed, with no damage during transit, and delivery was prompt. Overall, a reliable product for research applications.
Ethan Brooks –
By the end of the testing window, measurable reductions in abdominal fat indicators were documented. Overall, the results aligned with expected outcomes under structured conditions.
Dylan Carter –
The product quality appears consistent and stable under controlled laboratory conditions. Initial dosing calculations required some clarification, but once standardized, the compound performed as expected in our experimental protocol. Observed data trends aligned with anticipated outcomes over the study period.
Emily Zhao –
We did note minor stability sensitivity once reconstituted, so proper storage was important. Overall, it met our research expectations and produced measurable outcomes within the parameters we were monitoring.
Noah Kim –
It seems that consistent application and enough time are important when evaluating its effects in a laboratory setting.
Isabella Rossi –
I did not anticipate rapid changes within the initial observation period; however, after approximately four weeks of controlled laboratory protocol, measurable improvement in abdominal composition was noted.